Apogee secures $1.3b to advance dermatitis treatment
Apogee Therapeutics has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialisation of zumilokibart. Combined with company’s current total cash of $1.3 billion, the company… Read More